Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer

Yoshimura, Naoki; Kudoh, Shinzoh; Kimura, Tooru; Mitsuoka, Shigeki; Kyoh, Shigenori; Tochino, Yoshihiro; Asai, Kuniya; Kodama, Toyoki; Ichimaru, Yukikazu; Yana, Takashi; Hirata, Kazuto

doi:10.1097/jto.0b013e31819846e4

Cited by 17 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An interesting 43.3% 1-yr survival was also observed by Japanese investigators in patients aged over 70 yrs, with the monthly docetaxel-carboplatin doublet; a finding deserving further prospective studies with docetaxel doublets [108].…”

Section: Elderly Patients Deserve Active Treatmentsupporting

confidence: 58%

Update on nonsmall cell lung cancer

Zalcman

Bergot²,

Lechapt‐Zalcman³

2010

Eur Respir Rev

View full text Add to dashboard Cite

Section: Elderly Patients Deserve Active Treatmentsupporting

confidence: 58%

Update on nonsmall cell lung cancer

Zalcman

Bergot²,

Lechapt‐Zalcman³

2010

Eur Respir Rev

View full text Add to dashboard Cite

“…Yoshimura et al have recently reported the efficacy of combination chemotherapy of docetaxel and carboplatin in elderly patients (≥70) with advanced NSCLC [36]. That study reported a response rate of 46.7%, a median PFS of 4.4 months, and an OS of 9.9 months.…”

Section: Discussionmentioning

confidence: 99%

A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer

Kim¹,

Kim²,

Lee³

et al. 2010

Lung Cancer

View full text Add to dashboard Cite

“…Regardless of treatment, more neurotoxicity, pulmonary events, infection, anorexia, dehydration, and neuromotor issues were experienced by elderly patients in the study than by younger patients. In two phase ii trials of docetaxel-carboplatin in elderly patients (median age: 74-75 years), the median os ranged from 9.9 months to 13.1 months, and the orr was approximately 47% in both trials 77,78 . Common grades 3 and 4 toxicities in both trials included neutropenia and anemia.…”

Section: Taxanes In the Elderlymentioning

confidence: 99%

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Socinski¹

2014

Current Oncology

View full text Add to dashboard Cite

standard-of-care options, and no single standardof-care regimen is superior in the treatment of advanced nsclc 7-10 . Thus, physicians rely on numerous factors to optimize treatment strategies, including histology, age, performance status, cost, tolerability, and convenience. The combination of a platinum agent with a taxane-either solvent-based (sb) paclitaxel (Taxol: Bristol-Myers Squibb, Princeton, NJ, U.S.A.) or docetaxel (Taxotere: SanofiAventis, Bridgewater, NJ, U.S.A.)-has a proven efficacy and safety profile in advanced nsclc 6 . The sb-paclitaxel-carboplatin regimen is among those most commonly used for the first-line treatment of advanced nsclc in the United States 11 .Recently, nab-paclitaxel, a 130-nm albuminbound ("nab") form of paclitaxel designed to use endogenous albumin pathways to increase intratumoural concentrations of the active drug, demonstrated improved antitumour activity and tolerability compared with sb-paclitaxel when both were used in combination with carboplatin in the first-line treatment of patients with advanced nsclc 12 . Based on the results of a phase iii trial, nab-paclitaxel in combination with carboplatin was approved in 2012 as first-line therapy for the treatment of locally advanced or metastatic nsclc in patients who are not candidates for curative surgery or radiation therapy 12,13 . The present review summarizes the clinical experience to date with taxanes in the first-line treatment of nsclc. DISCUSSION Taxane-Platinum CombinationsIn landmark nsclc studies, overall response rates (orrs) were higher with taxane-platinum combinations than with other chemotherapy regimens ( Table i). Historically, sb-paclitaxel given in combination with carboplatin or cisplatin demonstrated a median overall survival (os) of 7.7-10 months and an orr of 17%-41% [7][8][9]11,14,[16][17][18]22 . ABSTRACTBased on demonstrated favourable risk-benefit profiles, taxanes remain a key component in the first-line standard of care for advanced non-smallcell lung cancer (nsclc) and nsclc subtypes. In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or metastatic nsclc. The approval was granted because of demonstrated improved antitumour activity and tolerability compared with solvent-based paclitaxelcarboplatin in a phase iii trial. This review focuses on the evolution of first-line taxane therapy for advanced nsclc and the new options and advances in taxane therapy that might address unmet needs in advanced nsclc.

show abstract

Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer

Abstract: Docetaxel combined with carboplatin was an active treatment with manageable toxicity for the treatment of elderly patients with chemotherapy-naive NSCLC.

Cited by 17 publications

References 16 publications

Update on nonsmall cell lung cancer

Update on nonsmall cell lung cancer

A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About